Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hypoglycemia

Hypoglycemia

Part of Diabetes

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hypoglycemia

54 trials tracked for Hypoglycemia: 13 in phase 3 or 4 and 4 with published results. The most-cited published study has 53 citations.

54Trials tracked
13Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 3 Phase 3 10 Phase 2 12 Phase 1 3 Other / NA 26
  1. Phase 3 A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects Completed · 53 cited
  2. Phase 3 G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes Completed · 22 cited
  3. Phase 3 Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics Completed · 22 cited
  4. Phase 3 G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes Completed · 8 cited
  5. Phase 4 Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride Completed
  6. Phase 4 Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery Completed
Show 44 more trials
  1. Phase 4 The Effect of Glucomannan Soluble Fiber on Glucose Homeostasis in Patients With Roux En Y (RNY) Gastric Bypass Surgery Completed
  2. Phase 3 Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents Completed
  3. Phase 3 Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia Completed
  4. Phase 3 A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus Completed
  5. Phase 3 Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children Completed
  6. Phase 3 Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM Completed
  7. Phase 3 A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D Completed
  8. Phase 2 Intravenous Exenatide (Byetta) During Surgery Completed
  9. Phase 2 Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia Completed
  10. Phase 2 MGA031, Sirolimus and Tacrolimus in Islet Transplantation Completed
  11. Phase 2 PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients Completed
  12. Phase 2 G-Pen™ for Hypoglycemia Rescue in T1D Patients Completed
  13. Phase 2 Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients Completed
  14. Phase 2 Islet Allotransplantation With Steroid Free Immunosuppression Completed
  15. Phase 2 Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients Completed
  16. Phase 2 Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D Completed
  17. Phase 2 Allogeneic Islet Cells Transplanted Onto the Omentum Completed
  18. Phase 2 Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia Completed
  19. Phase 2 Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes Completed
  20. Phase 1 A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus Completed
  21. Phase 1 A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus Completed
  22. Phase 1 Adrenergic System in Islet Transplantation Completed
  23. N/A Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia Completed
  24. N/A Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients Completed
  25. N/A Comparing the Effectiveness of Two Approaches to Preventing Severe Hypoglycemia in Patients With Type 2 Diabetes (PHT2) Completed
  26. N/A Post Bariatric Closed Loop Glucagon Trial Completed
  27. N/A Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes Completed
  28. N/A Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery Completed
  29. N/A Testing Glial Pathways to HAAF in Human Subjects Using Carbon 13 Magnetic Resonance Spectroscopy Completed
  30. N/A Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes Completed
  31. N/A The Impact of Renin-angiotensin System on Brain Activation During Hypoglycaemia in Healthy Men, a PET Study Completed
  32. N/A The Effectiveness of Multimedia Education on Hypoglycemic Management. Completed
  33. N/A Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes Completed
  34. N/A Maternal Lifestyle and Neonatal Hypoglycemia Completed
  35. N/A Impact of Hypoglycaemia in Patients With Diabetes Mellitus Type 2 on Platelet Activation Completed
  36. N/A Cognition in Patients With Hypoglycemia, Without Diabetes Completed
  37. N/A Glucagon and Advanced HCL System to Prevent Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes Completed
  38. N/A Reducing Treatment Risk in Older Adults With Diabetes Completed
  39. N/A Hypoglycemia (Low Blood Sugar) and the Heart Completed
  40. N/A Hypoglycemia and Autonomic Nervous System Function Completed
  41. N/A Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety After Gastric Surgery Completed
  42. N/A 24/7 Closed-loop in Older Subjects With Type 1 Diabetes Completed
  43. N/A Pilot Feasibility Study for HypoPals, a Mobile Health Program for Improving Hypoglycemia Management. Completed
  44. N/A CGM Use in Poorly Controlled Youth With Type 1 Diabetes Completed

Showing the 50 most-cited and recently-updated of 54 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Hypoglycemia: what the trials found

Dasiglucagon has been shown to significantly improve the speed and magnitude of glucose recovery following a hypoglycemic event. Trials demonstrated significant reductions in time to plasma glucose recovery [6, 11, 12] and significant increases in both the amount of plasma glucose recovered and the total change from baseline [6, 11, 12].

Nasal glucagon administration is associated with high rates of patients awakening or returning to a normal status within 30 minutes following administration [14, 15].

The addition of glucomannan was associated with a statistically significant reduction in blood glucose levels during mixed meal testing (p=0.0156), though it did not significantly change the percentage of time spent in a hypoglycemic state (p=0.99) 5.

Combination therapy of vildagliptin and metformin resulted in 100% of patients achieving a decrease of at least 0.3% in HbA1c over 12 weeks, with no significant difference in glycemic variability (MAGE) between groups 4.

Recent results — preliminary, needs further review

  • EnMPC (Ensemble Model Predictive Control) AP Controller showed 0% time spent below 54 mg/dL and 1.3% time spent below 70 mg/dL 2.
  • Phentolamine was evaluated in a Phase 1 trial 1.
  • Cholecalciferol was evaluated in a Phase 2 trial 16.

For the clinician treating this condition

  • Dasiglucagon is an effective intervention for rapid glucose recovery following hypoglycemia, significantly reducing time to recovery and increasing the magnitude of glucose increase compared to standard treatments.
  • Nasal glucagon provides a viable route for emergency treatment, with high rates of patients returning to normal status within 30 minutes.
  • While glucomannan may lower blood glucose levels during mixed meal testing, it does not significantly alter the duration of time spent in a hypoglycemic state.

AI synthesis of 5 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Continuous glucose monitoring may reduce mortality and hypoglycemia in ICU patients compared to point of care testing
Emergency Medicine Meta-analysis
Continuous glucose monitoring may reduce mortality and hypoglycemia in ICU patients compared to point of care testing Meta-analysis links continuous glucose monitoring to lower mortality risk in ICU patients
This meta-analysis evaluated continuous glucose monitoring versus point of care blood glucose measurements in ICU patients.
A new analysis suggests continuous glucose monitoring may lower mortality and hypoglycemia in ICU patients, though evidence remains very unc…
May 1, 2026
Admission blood glucose levels associated with NRDS severity in neonates
Pediatrics Cohort
Admission blood glucose levels associated with NRDS severity in neonates High blood sugar linked to worse breathing in newborns with lung distress
This retrospective cohort study of 219 neonates with NRDS at a tertiary hospital in China found that hyperglycemia at admission was associat…
Newborns with high blood sugar had more severe breathing trouble and needed longer support than those with normal sugar levels.
Frontiers Apr 23, 2026
Pilot RCT Shows Feasibility of Digital Hypoglycemia Intervention in Type 1 Diabetes
Diabetes & Endocrinology RCT
Pilot RCT Shows Feasibility of Digital Hypoglycemia Intervention in Type 1 Diabetes Can a digital program help people with type 1 diabetes manage low blood sugar?
A pilot randomized controlled trial in 40 adults with type 1 diabetes assessed the feasibility and acceptability of the HypoPals digital beh…
A new digital program helped 88% of adults with type 1 diabetes feel more confident managing low blood sugar while completing the full study…
Apr 3, 2026

Research across Diabetes

Related studies from across the Diabetes family.

Observational MRI study links impaired hypoglycemia awareness to blunted cerebral blood flow responses in type 1 diabetes
Diabetes & Endocrinology
Observational MRI study links impaired hypoglycemia awareness to blunted cerebral blood flow responses in type 1 diabetes Type 1 Diabetes Rewires How the Brain Responds to Low Blood Sugar
This observational study used hyperinsulinemic clamp with arterial spin-labeling MRI to compare cerebral blood flow responses to hypoglycemi…
Type 1 diabetes changes how the brain handles low blood sugar, and those who can't feel the danger show the most severe disruption in brain …
Apr 18, 2026